NK cells and polymorphonuclear neutrophils are both critical for IL-2-induced pulmonary vascular leak syndrome

Journal of Immunology

Volumn 172, Issue 12, 2004, Pages 7661-7668

  Assier, Eric ^a   Jullien, Valérie ^a   Lefort, Jean ^a   Moreau, Jean Louis ^a   Di Santo, James P ^a   Vargaftig, B Boris ^a   Lapa E Silva, Jose R ^b   Thèze, Jacques ^a  

^a INSTITUT PASTEUR   (France)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; INTERLEUKIN 2; MYELOPEROXIDASE; N(G) NITROARGININE METHYL ESTER;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; BRONCHUS HYPERREACTIVITY; ENZYME ACTIVITY; GRANULOCYTE; LUNG DISEASE; LUNG EDEMA; LUNG LAVAGE; LUNG TOXICITY; LUNG WEIGHT; LYMPHOCYTE DEPLETION; MOUSE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PATHOPHYSIOLOGY; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; SYNDROME DELINEATION; VASCULAR LEAK SYNDROME;

EID: 2942560498     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.12.7661     Document Type: Article

References (48)

1. Thèze, J., P. Alzari, and J. Bertoglio. 1996. IL-2 and IL-2 Receptors: recent advances and new immunological functions. Immunol. Today 17:481.
2. Li, X. C., G. Demirci, S. Ferrari-Lacraz, C. Groves, A. Coyle, T. R. Malek, and T. B. Strom. 2001. IL-15 and IL-2: a matter of life and death for T cells in vivo. Nat. Med. 7:114.
3. Lotze, M., Y. Matory, A. Rayner, S. Ettinghausen, J. Vetto, C. Seipp, and S. Rosenberg. 1986. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 58:2764.
4. Rosenberg, S. A., M. T. Lotze, L. M. Muul, A. E. Chang, F. P. Avis, S. Leitman, W. M. Linehan, C. N. Robertson, R. E. Lee, and J. T. Rubin. 1987. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med. 316:889.
5. Leef Jacobson, E., F. Pilaro, and K. A. Smith. 1996. Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity. Proc. Natl. Acad. Sci. USA 93:10-405.
6. David, D., L. Nait-Ighil, B. Dupont, J. Maral, B. Gachot, and J. Theze. 2001. Rapid effect of interleukin-2 therapy in human immunodeficiency virus-infected patients whose CD4 cell counts increase only slightly in response to combined antiretroviral treatment. J. Infect. Dis. 183:730.
7. + T cells. Blood 100:2159.
8. + T cells in vivo after IL-2 treatment of patients with HIV infection. Proc. Natl. Acad. Sci. USA 99:10712.
9. Smith, K. A. 2001. To cure chronic HIV infection, a new therapeutic strategy is needed. Curr. Opin. Immunol. 13:617.
10. Locker, G. J., S. Kapiotis, M. Veitl, R. M. Mader, B. Stoiser, J. Kofler, A. E. Sieder, H. Rainer, G. G. Steger, C. Mannhalter, et al. 1999. Activation of endothelium by immunotherapy with interleukin-2 in patients with malignant disorders. Br. J. Haematol. 105:912.
11. Lentsch, A., F. Miller, and M. Edwards. 1999. Mechanisms of leukocyte-mediated tissue injury induced by interleukin-2. Cancer Immunol. Immunother. 47:243.
12. Harada, Y., and I. Yahara. 1993. Pathogenesis of toxicity with human-derived interleukin-2 in experimental animals. Int. Rev. Exp. Pathol. 34:37.
13. Anderson, T. D., T. J. Hayes, G. D. Powers, M. K. Gately, R. Tudor, and A. Rushton. 1993. Comparative toxicity and pathology associated with administration of recombinant IL-2 to animals. Int. Rev. Exp. Pathol. 34:57.
14. ω -nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interleukin 2-induced capillary leak syndrome in healthy mice. J. Immunother. 18:210.
15. Orucevic, A., and P. K. Lala. 1996. b. N-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interleukin 2-induced capillary leakage and reduces tumour growth in adenocarcinoma-bearing mice. Br. J. Cancer 73:189.
16. ω-nitro-Larginine methyl ester inhibits inflammatory liver injury induced by interleukin-2. J. Leukocyte Biol. 63:22.
17. Cotran, R. S., J. S. Pober, M. A. J. Gimbrone, T. A. Springer, E. A. Wiebke, A. A. Gaspari, S. A. Rosenberg, and M. T. Lotze. 1988. Endothelial activation during interleukin 2 immunotherapy: a possible mechanism for the vascular leak syndrome. J. Immunol. 140:1883.
18. Baluna, R., J. Rizo, B. E. Gordon, V. Ghetie, and E. S. Vitetta. 1999. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc. Natl. Acad. Sci. USA 96:3957.
19. Baluna, R., and E. S. Vitetta. 1997. Vascular leak syndrome: a side effect of immunotherapy. Immunopharmacology 37:117.
20. Rosenstein, M., S. E. Ettinghausen, and S. A. Rosenberg. 1986. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J. Immunol. 137:1735.
21. Hammond-McKibben, D. M., A. Seth, P. S. Nagarkatti, and M. Nagarkatti. 1995. Characterization of factors regulating successful immunotherapy using a tumor-specific cytotoxic T lymphocyte clone: role of interleukin-2, cycling pattern of lyric activity and adhesion molecules. Int. J. Cancer 60:828.
22. Damle, N., L. Doyle, J. Bender, and E. Bradley. 1987. Interleukin 2-activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelial cells and cause their lysis. J. Immunol. 138:1779.
23. Damle, N. K., and L. V. Doyle. 1989. IL-2-activated human killer lymphocytes but not their secreted products mediate increase in albumin flux across cultured endothelial monolayers: implications for vascular leak syndrome. J. Immunol. 142:2660.
24. Peace, D. J., and M. A. Cheever. 1989. Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia. J. Exp. Med. 169:161.
25. Ehl, S., R. Nuesch, T. Tanaka, M. Myasaka, H. Hengartner, and R. Zinkemagel. 1996. A comparison of efficacy and specificity of three NK depleting antibodies. J. Immunol. Methods 199:149.
26. Gately, M. K., T. D. Anderson, and T. J. Hayes. 1988. Role of asialo-GM1-positive lymphoid cells in mediating the toxic effects of recombinant IL-2 in mice. J. Immunol. 141:189.
27. Rafi, A. Q., A. Zeytun, M. J. Bradley, D. P. Sponenberg, R. L. Grayson, M. Nagarkatti, and P. S. Nagarkatti. 1998. Evidence for the involvement of Fas ligand and perforin in the induction of vascular leak syndrome. J. Immunol. 161:3077.
28. Rafi-Janajreh, A. Q., D. Chen, R. Schmits, T. W. Mak, R. L. Grayson, D. P. Sponenberg, M. Nagarkatti, and P. S. Nagarkatti. 1999. Evidence for the involvement of CD44 in endothelial cell injury and induction of vascular leak syndrome by IL-2. J. Immunol. 163:1619.
29. Welboum, R., G. Goldman, L. Kobzik, C. R. Valeri, D. Shepro, and H. B. Hechtman. 1990. Involvement of thromboxane and neutrophils in multiple-system organ edema with interleukin-2. Ann. Surg. 212:728.
30. Ward, P. A. 1996. Role of complement, chemokines, and regulatory cytokines in acute lung injury. Ann. NY Acad. Sci. 796:104.
31. Ranson, T., C. Vosshenrich, E. Corcuff, O. Richard, V. Laloux, A. Lehuen, and J. P. Di Santo. 2003. IL-15 availability conditions homeostasis of peripheral natural killer T cells. Proc. Natl. Acad. Sci. USA 100:2663.
32. Hamelmann, E., J. Schwarze, K. Takeda, A. Oshiba, G. L. Larsen, C. G. Irvin, and E. W. Gelfand. 1997. Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am. J. Respir. Crit. Care Med. 156:766.
33. Warren, J. S., K. R. Yabroff, D. G. Remick, S. L. Kunkel, S. W. Chensue, R. G. Kunkel, K. J. Johnson, and P. A. Ward. 1989. Tumor necrosis factor participates in the pathogenesis of acute immune complex alveolitis in the rat. J. Clin. Invest. 84:1873.
34. Hirano, S. 1996. Migratory responses of PMN after intraperitoneal and intratracheal administration of lipopolysaccharide. Am. J. Physiol. 270:L836.
35. Lefort, J., M. Singer, D. Leduc, P. Renesto, M. A. Nahori, M. Huerre, C. Créminion, M. Chignard, and B. B. Vargaftig. 1998. Systemic administration of endotoxin induces bronchopulmonary hyperreactivity dissociated from TNF-α formation and neutrophil recruitment into the murine lungs. J. Immunol. 161:474.
36. Ranson, T., C. A. Vosshenrich, E. Corcuff, O. Richard, W. Muller, and J. P. Di Santo. 2003. IL-15 is an essential mediator of peripheral NK-cell homeostasis. Blood 101:4887.
37. Ettinghausen, S. E., J. G. Moore, D. E. White, L. Platanias, N. S. Young, and S. A. Rosenberg. 1987. Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients. Blood 69:1654.
38. Klausner, J., I. Paterson, N. Morel, G. Goldman, A. Gray, R. Valeri, T. Eberlein, D. Shepro, and H. Hechtman. 1989. Role of thromboxane in interleukin 2-induced lung injury in sheep. Cancer Res. 49:3542.
39. Orucevic, A., S. Heam, and P. K. Lala. 1997. The role of active inducible nitric oxide synthase expression in the pathogenesis of capillary leak syndrome resulting from interleukin-2 therapy in mice. Lab. Invest. 76:53.
40. G-methyl-L-arginine, an inhibitor of nitric oxide synthase, reverses interleukin-2-induced hypotension. Crit. Care Med. 23:1018.
41. Berthiaume, Y., P. Boiteau, G. Fick, R. Kloiber, G. D. Sinclair, C. Fong, M. C. Poon, and R. Lafreniere. 1995. Pulmonary edema during IL-2 therapy: combined effect of increased permeability and hydrostatic pressure. Am. J. Respir. Crit. Care Med. 152:329.
42. Lapa e Silva, J. R., M. D. Possebon da Silva, J. Lefort, and B. B. Vargaftig. 2000. Endotoxins, asthma, and allergic immune responses. Toxicology 152:31.
43. Allavena, P., G. Bianchi, D. Zhou, J. Van Damme, P. Jilek, S. Sozzani, and A. Mantovani. 1994. Induction of natural killer cell migration by monocyte chemotactic protein-1, -2 and -3. Eur. J. Immunol. 24:3233.
44. Larsson, R., D. Rocksen, B. Lilliehook, A. Jonsson, and A. Bucht. 2000. Dose-dependent activation of lymphocytes in endotoxin-induced airway inflammation. Infect. Immun. 68:6962.
45. Girard, D., N. Boiani, and A. D. Beaulieu. 1998. Human neutrophils express the interleukin-15 receptor a chain (IL-15Rα) but not the IL-9Rα component. Clin. Immunol. Immunopathol. 88:232.
46. Melani, C., M. Figini, D. Nicosia, E. Luison, V. Ramakrishna, G. Casorati, G. Parmiani, Z. Eshhar, S. Canevari, and M. P. Colombo. 1998. Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody. Cancer Res. 58:4146.
47. Eckenberg, R., J. L. Moreau, O. Melnyk, and J. Theze. 2000. IL-2Rβ agonist PI-30 acts in synergy with IL-2, IL-4, IL-9, and IL-15: biological and molecular effects. J. Immunol. 165:4312.
48. Eckenberg, R., T. Rose, J. L. Moreau, R. Weil, F. Gesbert, S. Dubois, D. Tello, M. Bossus, H. Gras, A. Tartar, et al. 2000. The first a helix of interleukin (IL)-2 folds as a homotetramer, acts as an agonist of the IL-2 receptor β chain, and induces lymphokine-activated killer cells. J. Exp. Med. 191:529.